Radiotherapy dose escalation improves tumour control in prostate cancer but with increased toxicity. Boosting focal tumour only may allow dose escalation with acceptable toxicity. Intensity-modulated radiotherapy can deliver this, but visualization of the tumour remains limiting. CT or conventional MRI techniques are poor at localizing tumour, but dynamic contrast-enhanced MRI (DCE-MRI) may be superior. 18 patients with prostate cancer had T(2) weighted (T2W) and DCE-MRI prior to prostatectomy. The prostate was sectioned meticulously so as to achieve accurate correlation between imaging and pathology. The accuracy of DCE-MRI for cancer detection was calculated by a pixel-by-pixel correlation of quantitative DCE-MRI parameter maps and pathology. In addition, a radiologist interpreted the DCE-MRI and T2W images. The location of tumour on imaging was compared with histology, and the accuracy of DCE-MRI and T2W images was then compared. Pixel-by-pixel comparison of quantitative parameter maps showed a significant difference between the benign peripheral zone and tumour for the parameters K(trans), v(e) and k(ep). Calculation of areas under the receiver operating characteristic curve showed that the pharmacokinetic parameters were only "fair" discriminators between cancer and benign gland. Interpretation of DCE-MRI and T2W images by a radiologist showed DCE-MRI to be more sensitive than T2W images for tumour localization (50\% vs 21\%; p = 0.006) and similarly specific (85\% vs 81\%; p = 0.593). The superior sensitivity of DCE-MRI compared with T2W images, together with its high specificity, is arguably sufficient for its use in guiding radiotherapy boosts in prostate cancer.
Academic Department of Radiotherapy and Oncology, Royal Marsden NHS Foundation Trust and Institute of Cancer Research, Sutton, UK. Andrew.Jackson@manchester.ac.uk
%0 Journal Article
%1 Jackson2009
%A Jackson, A S N
%A Reinsberg, Stefan A
%A Sohaib, S A
%A Charles-Edwards, E M
%A Jhavar, S
%A Christmas, T J
%A Thompson, A C
%A Bailey, M J
%A Corbishley, C M
%A Fisher, C
%A Leach, M O
%A Dearnaley, D P
%D 2009
%J Br. J. Radiol.
%K adenocarcinoma,adenocarcinoma aged,prostatectomy,prostatic assisted assisted,computer diagnosis,adenocarcinoma diagnosis,prostatic diagnostic dtpa dtpa,gadolinium imaging imaging,magnetic interpretation,magnetic media,gadolinium methods,contrast methods,male,middle myown neoplasms neoplasms,prostatic pathology,adenocarcinoma pathology,prostatic planning,sensitivity resonance specificity specificity,myown therapy,adult,aged,computer therapy,radiotherapy use,humans,image
%N 974
%P 148--56
%R 10.1259/bjr/89518905
%T Dynamic contrast-enhanced MRI for prostate cancer localization.
%U http://www.ncbi.nlm.nih.gov/pubmed/19168692
%V 82
%X Radiotherapy dose escalation improves tumour control in prostate cancer but with increased toxicity. Boosting focal tumour only may allow dose escalation with acceptable toxicity. Intensity-modulated radiotherapy can deliver this, but visualization of the tumour remains limiting. CT or conventional MRI techniques are poor at localizing tumour, but dynamic contrast-enhanced MRI (DCE-MRI) may be superior. 18 patients with prostate cancer had T(2) weighted (T2W) and DCE-MRI prior to prostatectomy. The prostate was sectioned meticulously so as to achieve accurate correlation between imaging and pathology. The accuracy of DCE-MRI for cancer detection was calculated by a pixel-by-pixel correlation of quantitative DCE-MRI parameter maps and pathology. In addition, a radiologist interpreted the DCE-MRI and T2W images. The location of tumour on imaging was compared with histology, and the accuracy of DCE-MRI and T2W images was then compared. Pixel-by-pixel comparison of quantitative parameter maps showed a significant difference between the benign peripheral zone and tumour for the parameters K(trans), v(e) and k(ep). Calculation of areas under the receiver operating characteristic curve showed that the pharmacokinetic parameters were only "fair" discriminators between cancer and benign gland. Interpretation of DCE-MRI and T2W images by a radiologist showed DCE-MRI to be more sensitive than T2W images for tumour localization (50\% vs 21\%; p = 0.006) and similarly specific (85\% vs 81\%; p = 0.593). The superior sensitivity of DCE-MRI compared with T2W images, together with its high specificity, is arguably sufficient for its use in guiding radiotherapy boosts in prostate cancer.
%@ ISSN\~\~82974148
@article{Jackson2009,
abstract = {Radiotherapy dose escalation improves tumour control in prostate cancer but with increased toxicity. Boosting focal tumour only may allow dose escalation with acceptable toxicity. Intensity-modulated radiotherapy can deliver this, but visualization of the tumour remains limiting. CT or conventional MRI techniques are poor at localizing tumour, but dynamic contrast-enhanced MRI (DCE-MRI) may be superior. 18 patients with prostate cancer had T(2) weighted (T2W) and DCE-MRI prior to prostatectomy. The prostate was sectioned meticulously so as to achieve accurate correlation between imaging and pathology. The accuracy of DCE-MRI for cancer detection was calculated by a pixel-by-pixel correlation of quantitative DCE-MRI parameter maps and pathology. In addition, a radiologist interpreted the DCE-MRI and T2W images. The location of tumour on imaging was compared with histology, and the accuracy of DCE-MRI and T2W images was then compared. Pixel-by-pixel comparison of quantitative parameter maps showed a significant difference between the benign peripheral zone and tumour for the parameters K(trans), v(e) and k(ep). Calculation of areas under the receiver operating characteristic curve showed that the pharmacokinetic parameters were only "fair" discriminators between cancer and benign gland. Interpretation of DCE-MRI and T2W images by a radiologist showed DCE-MRI to be more sensitive than T2W images for tumour localization (50{\%} vs 21{\%}; p = 0.006) and similarly specific (85{\%} vs 81{\%}; p = 0.593). The superior sensitivity of DCE-MRI compared with T2W images, together with its high specificity, is arguably sufficient for its use in guiding radiotherapy boosts in prostate cancer.},
added-at = {2018-10-29T06:43:31.000+0100},
author = {Jackson, A S N and Reinsberg, Stefan A and Sohaib, S A and Charles-Edwards, E M and Jhavar, S and Christmas, T J and Thompson, A C and Bailey, M J and Corbishley, C M and Fisher, C and Leach, M O and Dearnaley, D P},
biburl = {https://www.bibsonomy.org/bibtex/2e37daf9cd7fdc07d08cecf4db132a608/drsar},
doi = {10.1259/bjr/89518905},
institution = {Academic Department of Radiotherapy and Oncology, Royal Marsden NHS Foundation Trust and Institute of Cancer Research, Sutton, UK. Andrew.Jackson@manchester.ac.uk},
interhash = {c6534911386cef709da09a5d06560620},
intrahash = {e37daf9cd7fdc07d08cecf4db132a608},
isbn = {ISSN{\~{}}{\~{}}82974148},
issn = {1748880X},
journal = {Br. J. Radiol.},
keywords = {adenocarcinoma,adenocarcinoma aged,prostatectomy,prostatic assisted assisted,computer diagnosis,adenocarcinoma diagnosis,prostatic diagnostic dtpa dtpa,gadolinium imaging imaging,magnetic interpretation,magnetic media,gadolinium methods,contrast methods,male,middle myown neoplasms neoplasms,prostatic pathology,adenocarcinoma pathology,prostatic planning,sensitivity resonance specificity specificity,myown therapy,adult,aged,computer therapy,radiotherapy use,humans,image},
number = 974,
pages = {148--56},
pmid = {19168692},
timestamp = {2018-10-29T07:15:33.000+0100},
title = {{Dynamic contrast-enhanced MRI for prostate cancer localization.}},
url = {http://www.ncbi.nlm.nih.gov/pubmed/19168692},
volume = 82,
year = 2009
}